8-K Announcements
6Material company update
Mar 12, 2026·SEC
Material company update
Feb 13, 2026·SEC
Material company update
Feb 10, 2026·SEC
Nektar Therapeutics(NKTR)Earnings, Financials & Key Ratios
NKTR•NASDAQ
$84.16
$1.65B mkt cap·Price updated May 6, 2026
AboutNektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.Show more
- Revenue$55M-43.9%
- EBITDA-$140M-39.0%
- Net Income-$164M-37.9%
- EPS (Diluted)-9.73-12.1%
- EBITDA Margin-253.66%-147.7%
- Operating Margin-253.66%-137.3%
- Net Margin-297.07%-145.8%
- ROE-217.94%-75.6%
- ROIC-75.18%-58.4%
- Debt/Equity0.95-43.5%
NKTR Key Insights
Nektar Therapeutics (NKTR) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 94 (top 6%)
- ✓High quality earnings: Operating CF exceeds net income
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Sales declining 18.4% over 5 years
- ✗Shares diluted 23.0% in last year
- ✗Expensive at 15.8x book value
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
NKTR Price & Volume
Nektar Therapeutics (NKTR) stock price & volume — 10-year historical chart
Loading chart...
NKTR Growth Metrics
Nektar Therapeutics (NKTR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-13.32%
5 Years-18.43%
3 Years-15.66%
TTM-32.79%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM28.26%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM36.81%
Return on Capital
10 Years-21.91%
5 Years-37.65%
3 Years-41.07%
Last Year-59.7%
NKTR Recent Earnings
Nektar Therapeutics (NKTR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
Mar 12, 2026EPS
$1.78
Est $2.76
+35.5%
Revenue
$22M
Est $10M
+114.0%
Q4 2025
Nov 6, 2025EPS
$1.85
Est $2.85
+35.1%
Revenue
$12M
Est $10M
+12.9%
Q3 2025
Aug 7, 2025EPS
$2.95
Est $3.13
+5.8%
Revenue
$11M
Est $9M
+18.7%
Q2 2025
May 8, 2025EPS
$3.30
Est $2.70
-22.2%
Revenue
$10M
Est $15M
-31.9%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 12, 2026 | $1.78vs $2.76+35.5% | $22Mvs $10M+114.0% |
| Q4 2025 | Nov 6, 2025 | $1.85vs $2.85+35.1% | $12Mvs $10M+12.9% |
| Q3 2025 | Aug 7, 2025 | $2.95vs $3.13+5.8% | $11Mvs $9M+18.7% |
| Q2 2025 | May 8, 2025 | $3.30vs $2.70-22.2% | $10Mvs $15M-31.9% |
Based on last 12 quarters of dataView full earnings history →
NKTR Peer Comparison
Nektar Therapeutics (NKTR) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 HALO | 7.76B | 65.87 | 25.73 | 37.55% | 22.69% | 6.49% | 8.31% | |
 ARWR | 10.49B | 74.93 | -6141.80 | 232.58% | 18.54% | 35.64% | 1.5% | 0.73 |
 ALNY | 40.18B | 301.11 | 129.23 | 65.19% | 13.46% | 98.29% | 1.16% | 1.62 |
 IONS | 12.44B | 75.25 | -31.62 | 33.87% | -30.87% | -58.57% | 5.35 | |
 EXEL | 11.28B | 44.42 | 15.98 | 6.98% | 35.08% | 40.21% | 7.48% | 0.08 |
 INCY | 19.47B | 97.47 | 15.21 | 21.22% | 26.71% | 29.31% | 6.96% | 0.01 |
 RCUS | 2.62B | 26.06 | -7.92 | -4.26% | -156.36% | -68.97% | 0.16 | |
 IMVT | 5.66B | 27.84 | -10.20 | -47.07% | 0.00 |
Compare NKTR vs Peers
Nektar Therapeutics (NKTR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NKTR Income Statement
Nektar Therapeutics (NKTR) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 307.71M | 1.19B | 114.62M | 152.91M | 101.91M | 92.06M | 90.12M | 98.43M | 55.23M | 62.6M |
| Revenue Growth % | 86% | 287.81% | -90.4% | 33.41% | -33.36% | -9.67% | -2.1% | 9.22% | -43.89% | -32.79% |
| Cost of Goods Sold | 30.55M | 24.41M | 21.37M | 19.48M | 24.9M | 21.64M | 36.64M | 30.69M | 0 | 8.17M |
| COGS % of Revenue | 9.93% | 2.05% | 18.65% | 12.74% | 24.43% | 23.5% | 40.66% | 31.18% | - | - |
| Gross Profit | 277.16M▲ 0% | 1.17B▲ 321.7% | 93.24M▼ 92.0% | 133.44M▲ 43.1% | 77.01M▼ 42.3% | 70.42M▼ 8.6% | 53.48M▼ 24.1% | 67.74M▲ 26.7% | 0▼ 100.0% | 54.43M▲ 0% |
| Gross Margin % | 90.07% | 97.95% | 81.35% | 87.26% | 75.57% | 76.5% | 59.34% | 68.82% | - | 86.94% |
| Gross Profit Growth % | 104.97% | 321.74% | -92.02% | 43.11% | -42.29% | -8.56% | -24.06% | 26.67% | -100% | - |
| Operating Expenses | 320.82M | 480.98M | 533.28M | 513.36M | 523.11M | 310.66M | 190.9M | 172.94M | 186M | 152.38M |
| OpEx % of Revenue | 104.26% | 40.31% | 465.27% | 335.72% | 513.32% | 337.47% | 211.83% | 175.7% | 336.77% | - |
| Selling, General & Admin | 52.36M | 81.44M | 98.71M | 104.68M | 122.84M | 92.33M | 77.42M | 76.75M | 68.67M | 74.43M |
| SG&A % of Revenue | 17.02% | 6.82% | 86.12% | 68.46% | 120.55% | 100.3% | 85.9% | 77.98% | 124.34% | - |
| Research & Development | 268.46M | 399.54M | 434.57M | 408.68M | 400.27M | 218.32M | 114.16M | 120.91M | 117.33M | 116.36M |
| R&D % of Revenue | 87.24% | 33.48% | 379.15% | 267.26% | 392.78% | 237.17% | 126.68% | 122.84% | 212.43% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | -676K | -24.72M | 0 | -384K |
| Operating Income | -59.64M▲ 0% | 687.93M▲ 1253.4% | -440.04M▼ 164.0% | -379.92M▲ 13.7% | -446.1M▼ 17.4% | -240.24M▲ 46.1% | -137.43M▲ 42.8% | -105.2M▲ 23.5% | -140.1M▼ 33.2% | -97.95M▲ 0% |
| Operating Margin % | -19.38% | 57.65% | -383.92% | -248.45% | -437.76% | -260.97% | -152.49% | -106.88% | -253.66% | -156.47% |
| Operating Income Growth % | 47.15% | 1253.44% | -163.96% | 13.66% | -17.42% | 46.15% | 42.8% | 23.45% | -33.18% | - |
| EBITDA | -47.04M | 696.73M | -429.04M | -367.42M | -431.96M | -228.04M | -129.61M | -100.81M | -140.1M | -96.78M |
| EBITDA Margin % | -15.29% | 58.39% | -374.32% | -240.28% | -423.87% | -247.72% | -143.82% | -102.42% | -253.66% | -154.6% |
| EBITDA Growth % | 52.8% | 1581.09% | -161.58% | 14.36% | -17.56% | 47.21% | 43.16% | 22.22% | -38.98% | 34.32% |
| D&A (Non-Cash Add-back) | 12.6M | 8.8M | 11M | 12.5M | 14.15M | 12.2M | 7.82M | 4.39M | 0 | 1.17M |
| EBIT | -55.12M | 725.5M | -393.7M | -406.83M | -475.97M | -336.07M | -250.92M | -91.09M | 0 | -87.75M |
| Net Interest Income | -36.43M | -5.21M | -19K | -18.84M | -44.58M | -22.13M | -6.33M | -13.61M | 0 | -15.96M |
| Interest Income | 4.52M | 37.57M | 46.34M | 18.28M | 2.73M | 6.78M | 19.01M | 14.5M | 10.44M | 10.6M |
| Interest Expense | 40.95M | 42.78M | 46.35M | 37.12M | 47.31M | 28.91M | 25.33M | 28.11M | -26.18M | 26.57M |
| Other Income/Expense | -36.43M | -5.21M | -19K | -64.03M | -77.18M | -124.75M | -138.83M | -14M | -15.38M | -23.21M |
| Pretax Income | -96.08M▲ 0% | 682.73M▲ 810.6% | -440.05M▼ 164.5% | -443.95M▼ 0.9% | -523.28M▼ 17.9% | -364.98M▲ 30.3% | -276.26M▲ 24.3% | -119.2M▲ 56.9% | -155.49M▼ 30.4% | -121.16M▲ 0% |
| Pretax Margin % | -31.22% | 57.21% | -383.93% | -290.32% | -513.49% | -396.48% | -306.54% | -121.1% | -281.52% | -193.55% |
| Income Tax | 616K | 1.41M | 613K | 493K | 557K | 3.21M | -200K | -239K | 8.59M | -428K |
| Effective Tax Rate % | -0.64% | 0.21% | -0.14% | -0.11% | -0.11% | -0.88% | 0.07% | 0.2% | -5.52% | 0.35% |
| Net Income | -96.69M▲ 0% | 681.31M▲ 804.6% | -440.67M▼ 164.7% | -444.44M▼ 0.9% | -523.84M▼ 17.9% | -368.2M▲ 29.7% | -276.06M▲ 25.0% | -118.96M▲ 56.9% | -164.08M▼ 37.9% | -120.74M▲ 0% |
| Net Margin % | -31.42% | 57.09% | -384.47% | -290.65% | -514.03% | -399.98% | -306.31% | -120.86% | -297.07% | -192.87% |
| Net Income Growth % | 37.02% | 804.62% | -164.68% | -0.86% | -17.86% | 29.71% | 25.03% | 56.91% | -37.92% | 28.26% |
| Net Income (Continuing) | -96.69M | 681.31M | -440.67M | -444.44M | -523.84M | -368.2M | -276.06M | -118.96M | -164.08M | -120.74M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -9.30▲ 0% | 56.70▲ 709.7% | -37.80▼ 166.7% | -37.33▲ 1.2% | -42.90▼ 14.9% | -29.51▲ 31.2% | -21.79▲ 26.2% | -8.68▲ 60.2% | -9.73▼ 12.1% | -8.57▲ 0% |
| EPS Growth % | 43.64% | 709.68% | -166.67% | 1.24% | -14.92% | 31.21% | 26.16% | 60.17% | -12.1% | 36.81% |
| EPS (Basic) | -9.30 | 56.70 | -37.80 | -37.33 | -42.90 | -29.51 | -21.79 | -8.68 | -9.73 | - |
| Diluted Shares Outstanding | 10.4M | 12.01M | 11.67M | 11.91M | 12.22M | 12.48M | 12.67M | 13.71M | 16.87M | 14.09M |
| Basic Shares Outstanding | 10.4M | 12.01M | 11.67M | 11.91M | 12.22M | 12.48M | 12.67M | 13.71M | 16.87M | 14.09M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
NKTR Balance Sheet
Nektar Therapeutics (NKTR) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 326.82M | 1.44B | 1.42B | 1.14B | 795.58M | 545.97M | 330.7M | 261.29M | 266.27M | 281.36M |
| Cash & Short-Term Investments | 296.13M | 1.34B | 1.32B | 1.06B | 733.96M | 504.98M | 303.62M | 255.23M | 245.75M | 270.21M |
| Cash Only | 4.76M | 194.91M | 96.36M | 198.96M | 25.22M | 88.23M | 35.28M | 44.25M | 15.12M | 41.03M |
| Short-Term Investments | 291.37M | 1.14B | 1.23B | 862.94M | 708.74M | 416.75M | 268.34M | 210.97M | 230.64M | 229.18M |
| Accounts Receivable | 5.01M | 43.21M | 36.8M | 38.89M | 22.49M | 8.4M | 2.25M | 1.61M | 0 | 1.29M |
| Days Sales Outstanding | 5.95 | 13.22 | 117.2 | 92.83 | 80.56 | 33.32 | 9.12 | 5.97 | - | 8.69 |
| Inventory | 10.73M | 11.38M | 12.66M | 15.29M | 15.8M | 19.2M | 16.1M | 0 | 0 | 0 |
| Days Inventory Outstanding | 128.16 | 170.16 | 216.28 | 286.57 | 231.65 | 323.95 | 160.38 | - | - | - |
| Other Current Assets | 14.35M | 21.29M | 15.39M | 0 | 0 | 0 | 0 | 0 | 20.51M | 0 |
| Total Non-Current Assets | 182.05M | 712.49M | 555.81M | 400.76M | 321.61M | 164.63M | 67.33M | 42.56M | 14.14M | 19.99M |
| Property, Plant & Equipment | 47.46M | 48.85M | 199.84M | 186.14M | 177.53M | 85.89M | 36.86M | 11.82M | 5M | 10M |
| Fixed Asset Turnover | 6.48x | 24.43x | 0.57x | 0.82x | 0.57x | 1.07x | 2.44x | 8.32x | 11.04x | 5.75x |
| Goodwill | 76.5M | 76.5M | 76.5M | 76.5M | 76.5M | 76.5M | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 57.09M | 582.89M | 279.12M | 136.66M | 64.83M | 0 | 25.82M | 26.09M | 0 | 46.07M |
| Other Non-Current Assets | 994K | 4.24M | 344K | 1.46M | 2.74M | 2.25M | 4.64M | 4.65M | 9.14M | 20.22M |
| Total Assets | 508.87M▲ 0% | 2.15B▲ 322.5% | 1.98B▼ 8.0% | 1.54B▼ 22.2% | 1.12B▼ 27.4% | 710.6M▼ 36.4% | 398.03M▼ 44.0% | 303.85M▼ 23.7% | 280.41M▼ 7.7% | 301.35M▲ 0% |
| Asset Turnover | 0.60x | 0.55x | 0.06x | 0.10x | 0.09x | 0.13x | 0.23x | 0.32x | 0.20x | 0.23x |
| Asset Growth % | -10.55% | 322.54% | -8.04% | -22.18% | -27.4% | -36.39% | -43.99% | -23.66% | -7.72% | -100.66% |
| Total Current Liabilities | 56.16M | 82M | 353.89M | 115.78M | 85.2M | 68.2M | 51.27M | 61.4M | 53.54M | 66.34M |
| Accounts Payable | 4.78M | 5.85M | 19.23M | 22.14M | 9.75M | 12.98M | 9.85M | 11.56M | 0 | 15.56M |
| Days Payables Outstanding | 57.14 | 87.53 | 328.46 | 414.89 | 142.89 | 218.98 | 98.09 | 137.5 | - | 661.38 |
| Short-Term Debt | 0 | 0 | 252.89M | 0 | 0 | 0 | 0 | 0 | 20.5M | 0 |
| Deferred Revenue (Current) | 18.95M | 13.89M | 5.52M | 91K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 24.17M | 52.32M | 11.47M | 14.44M | 15.73M | 9.58M | 5.55M | 5.55M | 33.04M | 8.61M |
| Current Ratio | 5.82x | 17.53x | 4.02x | 9.83x | 9.34x | 8.00x | 6.45x | 4.26x | 4.97x | 4.97x |
| Quick Ratio | 5.63x | 17.39x | 3.98x | 9.70x | 9.15x | 7.72x | 6.14x | 4.26x | 4.97x | 4.97x |
| Cash Conversion Cycle | 76.97 | 95.86 | 5.02 | -35.49 | 169.31 | 138.29 | 71.41 | - | - | -652.69 |
| Total Non-Current Liabilities | 364.88M | 350.6M | 218.07M | 345.69M | 352.48M | 275.76M | 215.78M | 181.71M | 137.04M | 149.92M |
| Long-Term Debt | 245.21M | 246.95M | 0 | 0 | 0 | 0 | 0 | 0 | 65.26M | 0 |
| Capital Lease Obligations | 0 | 0 | 142.73M | 136.37M | 125.74M | 112.83M | 98.52M | 82.7M | 0 | 305.07M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 100.65M | 92.9M | 72.79M | 206.86M | 226.75M | 162.93M | 117.26M | 99.02M | 71.78M | 358.49M |
| Total Liabilities | 421.04M | 432.6M | 571.97M | 461.47M | 437.68M | 343.96M | 267.05M | 243.11M | 190.57M | 216.26M |
| Total Debt | 245.21M | 246.95M | 408.14M | 150.29M | 143.18M | 131.5M | 117.78M | 102.56M | 85.75M | 91.92M |
| Net Debt | 240.44M | 52.05M | 311.77M | -48.67M | 117.96M | 43.27M | 82.5M | 58.31M | 70.64M | 50.88M |
| Debt / Equity | 2.79x | 0.14x | 0.29x | 0.14x | 0.21x | 0.36x | 0.90x | 1.69x | 0.95x | 0.95x |
| Debt / EBITDA | - | 0.35x | - | - | - | - | - | - | - | -0.95x |
| Net Debt / EBITDA | - | 0.07x | - | - | - | - | - | - | - | -0.53x |
| Interest Coverage | -1.46x | 16.08x | -9.49x | -10.24x | -9.43x | -8.31x | -5.42x | -3.74x | - | -3.30x |
| Total Equity | 87.83M▲ 0% | 1.72B▲ 1855.6% | 1.41B▼ 18.2% | 1.08B▼ 23.3% | 679.51M▼ 36.9% | 366.64M▼ 46.0% | 130.99M▼ 64.3% | 60.74M▼ 53.6% | 89.83M▲ 47.9% | 85.09M▲ 0% |
| Equity Growth % | -0.34% | 1855.61% | -18.18% | -23.35% | -36.92% | -46.04% | -64.27% | -53.63% | 47.9% | -199.11% |
| Book Value per Share | 8.45 | 143.04 | 120.47 | 90.49 | 55.61 | 29.39 | 10.34 | 4.43 | 5.32 | 6.04 |
| Total Shareholders' Equity | 87.83M | 1.72B | 1.41B | 1.08B | 679.51M | 366.64M | 130.99M | 60.74M | 89.83M | 85.09M |
| Common Stock | 15K | 17K | 17K | 18K | 19K | 19K | 19K | 19K | 2K | 2K |
| Retained Earnings | -2.12B | -1.42B | -1.86B | -2.31B | -2.83B | -3.2B | -3.48B | -3.6B | -3.76B | -3.72B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -3M | 0 | 0 |
| Accumulated OCI | -2.11M | -6.32M | -1M | -2.29M | -4.16M | -6.91M | 80K | 61K | 17K | 56K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NKTR Cash Flow Statement
Nektar Therapeutics (NKTR) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -80.41M | 718.21M | -328.68M | -313.29M | -412.66M | -304.01M | -192.61M | -175.71M | -208.51M | -208.51M |
| Operating CF Margin % | -26.13% | 60.19% | -286.76% | -204.88% | -404.94% | -330.25% | -213.72% | -178.52% | -377.52% | - |
| Operating CF Growth % | 31.28% | 993.15% | -145.76% | 4.68% | -31.72% | 26.33% | 36.64% | 8.77% | -18.67% | -32.91% |
| Net Income | -96.69M | 681.31M | -440.67M | -444.44M | -523.84M | -368.2M | -276.06M | -118.96M | -164.08M | -120.74M |
| Depreciation & Amortization | 14.74M | 10.87M | 13.16M | 14.18M | 14.15M | 13.03M | 7.82M | 4.39M | -4.49M | 299K |
| Stock-Based Compensation | 36.62M | 88.1M | 99.8M | 94.26M | 94.67M | 57.32M | 33.39M | 21.61M | 12.65M | 15.26M |
| Deferred Taxes | 15.08M | 0 | 0 | 20.35M | 8.02M | 2.71M | -140K | 0 | 0 | 0 |
| Other Non-Cash Items | -12.54M | -23.06M | -22.65M | -14.35M | 17.41M | -9.36M | 62.19M | -76.51M | -52.6M | -59.15M |
| Working Capital Changes | -37.62M | -39.01M | 21.69M | 16.71M | -23.08M | 492K | -19.8M | -6.24M | 0 | -25.41M |
| Change in Receivables | 10.66M | -25.5M | 6.41M | 1.91M | 12.4M | 16.51M | 4.78M | -3.04M | 0 | -2.2M |
| Change in Inventory | 383K | -655K | -1.28M | -2.63M | -509K | -3.4M | 699K | 497K | 0 | 1.3M |
| Change in Payables | 2.07M | 971K | 12.97M | 2.38M | -11.69M | 3.1M | -2.88M | 2.67M | -625K | 7.86M |
| Cash from Investing | -28.81M | -1.38B | 206.89M | 496.21M | 202.78M | 365.83M | 139.56M | 142.57M | -1.2M | 58.65M |
| Capital Expenditures | -9.68M | -14.24M | -26.29M | -7.26M | -14.99M | -5.68M | -865K | -1.47M | -171K | -612K |
| CapEx % of Revenue | 3.14% | 1.19% | 22.93% | 4.75% | 14.71% | 6.17% | 0.96% | 1.49% | 0.31% | - |
| Acquisitions | 0 | 2.63M | 0 | -503.47M | -217.77M | 13.2M | 0 | 65.39M | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -19.13M | 2.63M | 0 | 503.47M | 217.77M | 0 | 1.25M | 0 | -697K | 64.69M |
| Cash from Financing | 54.39M | 851.97M | 23.36M | -80.35M | 36.24M | 1.51M | 30K | 42.12M | 180.57M | 141.98M |
| Debt Issued (Net) | -5.13M | 0 | 0 | -103.75M | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 1000K | 0 | 1000K | 1000K | 758K | 30K | -1000K | 0 | 1.22M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -3M | 0 | 0 |
| Other Financing | 59.52M | 61.73M | 23.36M | 0 | 3M | 750K | 0 | 45.12M | 180.57M | 83K |
| Net Change in Cash | -54.88M▲ 0% | 190.14M▲ 446.5% | -98.54M▼ 151.8% | 102.59M▲ 204.1% | -173.74M▼ 269.3% | 63.01M▲ 136.3% | -52.95M▼ 184.0% | 8.97M▲ 116.9% | -29.14M▼ 424.6% | 10.92M▲ 0% |
| Free Cash Flow | -90.09M▲ 0% | 703.98M▲ 881.4% | -354.97M▼ 150.4% | -320.55M▲ 9.7% | -427.65M▼ 33.4% | -309.68M▲ 27.6% | -193.47M▲ 37.5% | -177.18M▲ 8.4% | -208.68M▼ 17.8% | -190.35M▲ 0% |
| FCF Margin % | -29.28% | 58.99% | -309.7% | -209.62% | -419.65% | -336.41% | -214.68% | -180.01% | -377.83% | -304.08% |
| FCF Growth % | 27% | 881.41% | -150.42% | 9.7% | -33.41% | 27.58% | 37.53% | 8.42% | -17.78% | -7.05% |
| FCF per Share | -8.67 | 58.63 | -30.43 | -26.92 | -35.00 | -24.82 | -15.27 | -12.92 | -12.37 | -12.37 |
| FCF Conversion (FCF/Net Income) | 0.83x | 1.05x | 0.75x | 0.70x | 0.79x | 0.83x | 0.70x | 1.48x | 1.27x | 1.58x |
| Interest Paid | 20.12M | 19.47M | 19.2M | 9.74M | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 556K | 618K | 555K | 539K | 325K | 272K | 2.66M | 76K | 0 | 76K |
NKTR Key Ratios
Nektar Therapeutics (NKTR) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -109.91% | 75.47% | -28.22% | -35.8% | -59.64% | -70.39% | -110.95% | -124.1% | -217.94% | -356.81% |
| Return on Invested Capital (ROIC) | -14.78% | 49.19% | -18.93% | -20.75% | -36.64% | -29.85% | -33.07% | -47.45% | -75.18% | -75.18% |
| Gross Margin | 90.07% | 97.95% | 81.35% | 87.26% | 75.57% | 76.5% | 59.34% | 68.82% | - | 86.94% |
| Net Margin | -31.42% | 57.09% | -384.47% | -290.65% | -514.03% | -399.98% | -306.31% | -120.86% | -297.07% | -192.87% |
| Debt / Equity | 2.79x | 0.14x | 0.29x | 0.14x | 0.21x | 0.36x | 0.90x | 1.69x | 0.95x | 0.95x |
| Interest Coverage | -1.46x | 16.08x | -9.49x | -10.24x | -9.43x | -8.31x | -5.42x | -3.74x | - | -3.30x |
| FCF Conversion | 0.83x | 1.05x | 0.75x | 0.70x | 0.79x | 0.83x | 0.70x | 1.48x | 1.27x | 1.58x |
| Revenue Growth | 86% | 287.81% | -90.4% | 33.41% | -33.36% | -9.67% | -2.1% | 9.22% | -43.89% | -32.79% |
NKTR SEC Filings & Documents
Nektar Therapeutics (NKTR) SEC filings — annual & quarterly reports (10-K, 10-Q)
NKTR Frequently Asked Questions
Nektar Therapeutics (NKTR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Nektar Therapeutics (NKTR) reported $62.6M in revenue for fiscal year 2025. This represents a 807% increase from $6.9M in 1996.
Nektar Therapeutics (NKTR) saw revenue decline by 43.9% over the past year.
Nektar Therapeutics (NKTR) reported a net loss of $120.7M for fiscal year 2025.
Dividend & Returns
Nektar Therapeutics (NKTR) has a return on equity (ROE) of -217.9%. Negative ROE indicates the company is unprofitable.
Nektar Therapeutics (NKTR) had negative free cash flow of $190.4M in fiscal year 2025, likely due to heavy capital investments.
Explore More NKTR
Nektar Therapeutics (NKTR) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates